B cell targeting therapies like rituximab (anti-CD20 mAb), belimumab (anti-BAFF mAb), and WT TACI-Fc fusion proteins (atacicept and telitacicept) have demonstrated promising therapeutic potential in various clinical studies, particularly for lupus, given its strong association with pathogenic B cells (38–45). This evidence concerns the gene TNFRSF13B and systemic lupus erythematosus.